Evidence map›Paper›PMID 34433711›Full record

ArticleInternal medicine (Tokyo, Japan)2022

A Rare Case of Acute Fibrinous and Organizing Pneumonia Associated with Systemic Lupus Erythematosus and Autoimmune-associated Hemophagocytic Syndrome: The Involvement of CD163-positive Macrophages.

Mariko Taira, Takeshi Matsumura, Yoshiko Sumita, Mayuko Moriyama, Masahiro Kondo, Noriyoshi Ishikawa, Yasuko Wada, Mamiko Nagase, Emiko Nishikawa, Yukari Tsubata and 2 more

Open access · diamondAbstract readCase Reports
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Frontiers in medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Mariko TairaDepartment of Rheumatology, Shimane University Faculty of Medicine, Japan.
Takeshi MatsumuraDepartment of Rheumatology, Shimane University Faculty of Medicine, Japan.
Yoshiko SumitaDepartment of Rheumatology, Shimane University Faculty of Medicine, Japan.
Mayuko MoriyamaDepartment of Rheumatology, Shimane University Faculty of Medicine, Japan.
Masahiro KondoDepartment of Rheumatology, Shimane University Faculty of Medicine, Japan.
Noriyoshi IshikawaDepartment of Surgical Pathology, Shimane University Faculty of Medicine, Japan.
Yasuko WadaInternal Medicine III, Shimane University Faculty of Medicine, Japan.
Mamiko NagaseOrgan Pathology, Shimane University Faculty of Medicine, Japan.
Emiko NishikawaRespiratory Medicine & Medical Oncology, Shimane University Faculty of Medicine, Japan.
Yukari TsubataRespiratory Medicine & Medical Oncology, Shimane University Faculty of Medicine, Japan.
Koji KishimotoThoracic Surgery, Shimane University Faculty of Medicine, Japan.
Yohko MurakawaDepartment of Rheumatology, Shimane University Faculty of Medicine, Japan.
Shimane University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Acute fibrinous and organizing pneumonia (AFOP) is rare in patients with systemic lupus erythematosus (SLE). We herein report a case of AFOP with SLE and hemophagocytic syndrome. Early-phase high-resolution computed tomography showed a fine granular lung pattern. A pathological examination revealed AFOP. An immunohistological examination revealed numerous CD163+ and fewer CD68+ macrophages present in the lung tissue and in alveolar spaces as well, including fibrin balls, the interstitium, and bronchial walls. Pneumonia and thrombocytopenia worsened during high-dose steroid therapy, plasma exchange, and intravenous immunoglobulin administration. The addition of intravenous cyclophosphamide successfully ameliorated the symptoms and radiographic lesions. Therefore, this therapy may be useful for treating severe AFOP.

Indexed as

Lupus Erythematosus, SystemicLymphohistiocytosis, HemophagocyticPneumoniaAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenHumansMacrophagesReceptors, Cell SurfaceAntigens, CDAntigens, Differentiation, MyelomonocyticCD163 AntigenReceptors, Cell Surfaceacute fibrinous and organizing pneumoniaautoimmune-associated hemophagocytic syndromeCD163 positive macrophagesintravenous cyclophosphamiderheumatic diseasesystemic lupus erythematosus

Identifiers

PMID34433711
PMCPMC8907772
OpenAlexW3195643632

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.